Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Geron Corp (GERN) Com Stk USD0.001

Sell:$1.43 Buy:$1.44 Change: $0.045 (3.04%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.43
Buy:$1.44
Change: $0.045 (3.04%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.43
Buy:$1.44
Change: $0.045 (3.04%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Geron Corporation (Geron) is a late-stage clinical biopharmaceutical company, which is focused on development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat includes IMerge, a Phase II/III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis.

Contact details

Address:
919 EAST HILLSDALE BOULEVARD, SUITE 250
FOSTER CITY
94404
United States
Telephone:
+1 (650) 4737700
Website:
www.geron.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GERN
ISIN:
US3741631036
Market cap:
$445.94 million
Shares in issue:
318.53 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • John Scarlett
    Chairman of the Board, President, Chief Executive Officer
  • Olivia Bloom
    Chief Financial Officer, Executive Vice President - Finance, Treasurer
  • Andrew Grethlein
    Executive Vice President, Chief Operating Officer
  • Stephen Rosenfield
    Executive Vice President, Corporate Secretary, Chief Legal Officer
  • Anil Kapur
    Executive Vice President, Corporate Strategy and Chief Commercial Officer
  • Melissa Kelly Behrs
    Executive Vice President, Chief Business Officer
  • Aleksandra Rizo
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.